Novel therapeutic strategies targeting HIV integrase

by Quashie, Peter K, Sloan, Richard D, Wainberg, Mark A
Published 2012

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity

by Singhroy, Diane N, Mesplède, Thibault, Sabbah, Arielle, Quashie, Peter K, Falgueyret, Jean-Pierre, Wainberg, Mark A
Published 2013

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

by Wares, Melissa, Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Wainberg, Mark A
Published 2014

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

by Quashie, Peter K., Han, Ying-Shan, Hassounah, Said, Mesplède, Thibault, Wainberg, Mark A.
Published 2015

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

by Wainberg, Mark, Anstett, Kaitlin, Mesplede, Thibault, Quashie, Peter, Han, Yingshan, Oliveira, Maureen
Published 2014

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M

by Depatureaux, Agnès, Mesplède, Thibault, Quashie, Peter, Oliveira, Maureen, Moisi, Daniela, Brenner, Bluma, Wainberg, Mark
Published 2014

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

by Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Singhroy, Diane N, Lie, Yolanda, Petropoulos, Christos J, Huang, Wei, Wainberg, Mark A
Published 2013